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Abstract
Children with sickle cell anemia (SCA) and conditional transcranial Doppler (TCD) ultrasound 
velocities (170-199 cm/sec) may develop stroke. However, with limited available clinical data, the 
current standard of care for conditional TCD velocities is observation. The efficacy of 
hydroxyurea in preventing conversion from conditional to abnormal TCD (≥200 cm/sec), which 
confers a higher stroke risk, has not been studied prospectively in a randomized trial. Sparing 
Conversion to Abnormal TCD Elevation (SCATE #NCT01531387) was an NHLBI-funded Phase 
III multicenter international clinical trial comparing alternative therapy (hydroxyurea) to standard 
care (observation) to prevent conversion from conditional to abnormal TCD velocity in children 
with SCA. SCATE enrolled 38 children from the United States, Jamaica, and Brazil [HbSS (36), 
HbSβ0-thalassemia (1), and HbSD (1), median age 5.4 years (range, 2.7-9.8)]. Due to slow patient 
accrual and administrative delays, SCATE was terminated early. In an intention-to-treat analysis, 
the cumulative incidence of abnormal conversion was 9% (95% CI 0 to 35%) in the hydroxyurea 
arm and 47% (95% CI 6 to 81%) in observation arm at 15 months (p=0.16). In post-hoc analysis 
according to treatment received, significantly fewer children on hydroxyurea converted to 
abnormal TCD velocities, compared to observation (0% versus 50%, p=0.02). After a mean of 
10.1 months, a significant change in mean TCD velocity was observed with hydroxyurea 
treatment (−15.5 versus +10.2 cm/sec, p=0.02). No stroke events occurred in either arm. 
Hydroxyurea reduces TCD velocities in children with SCA and conditional velocities.
Keywords
Conditional TCD; stroke; sickle cell disease; SCATE; TAMV
INTRODUCTION
Since the implementation of screening programs with transcranial Doppler examinations, the 
number of first strokes in children with sickle cell anemia (SCA) has significantly 
decreased. Identification of high risk patients (abnormal time-averaged mean velocity, 
TAMV ≥ 200 cm/sec) followed by chronic blood transfusion therapy, has effectively 
prevented most primary strokes.(1;2) Patients with abnormal TCD velocities are at highest 
risk for developing cerebrovascular accidents; however, stroke events can also occur among 
children whose last screening TCD examinations document conditional velocities (TAMV 
170 - 199 cm/sec).(3;4) Although their risk of primary stroke is lower relative to patients 
with abnormal TCD velocities (2 - 5% versus 9% per year), there are more patients with 
conditional than abnormal TCD velocities (prevalence 17% versus 9%), and the absolute 
number of children who might develop stroke is roughly equivalent between these two 
screening categories.(3;5-7)
Although conditional TCD velocities represent a moderate risk for developing primary 
stroke,(3;6) the current approach is clinical observation without specific disease-modifying 
therapy. However, the risk of TCD conversion from conditional to abnormal velocities is 
substantial and ranges from 15-55%.(7) Once conversion occurs, the established treatment is 
chronic transfusion therapy,(4) posing a substantial burden to patients and families, 
especially in resource-limited nations with an inadequate or less safe blood supply.
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There is evidence that hydroxyurea can reduce TCD velocities in children with SCA,(8-13) 
but further investigation is necessary to define the efficacy of hydroxyurea for preventing 
conversion from conditional to abnormal TCD velocities, thereby preventing the transition 
from moderate to high stroke risk category. Successfully preventing conversion to abnormal 
TCD velocities with hydroxyurea would avoid exposure to prolonged blood transfusion and 
its known complications (e.g., iron overload, alloimmunization, and infections). Prevention 
of abnormal TCD conversion would, therefore, represent a significant improvement in the 
medical management of children with SCA at moderate risk for stroke, and ultimately 
reduce medical costs while simultaneously providing an established effective preventive 
treatment for other sickle-related medical complications (e.g., painful events).
Sparing Conversion to Abnormal TCD Elevation (SCATE, Clinical trials.gov 
NCT01531387) was a National Heart, Lung, and Blood Institute (NHLBI)-funded Phase III 
multicenter international randomized clinical trial that compared alternative therapy 
(hydroxyurea) to standard care (observation) to prevent conversion of TCD velocities from 
the conditional to the abnormal range in children with SCA. SCATE enrolled children from 
the United States (US), Jamaica, and Brazil. This study was terminated early due to slow 
patient accrual and a low likelihood of reaching the primary study endpoint. However, even 
with challenges of low patient accrual and regulatory difficulties that limited the number of 
participants who actually received hydroxyurea therapy, a significant reduction in TCD 
velocities and abnormal TCD conversion were observed in the hydroxyurea-treated group. 
These findings suggest that hydroxyurea represents a potential treatment choice for children 
with conditional TCD velocities, to help reduce the risk of first stroke.
METHODS
Patient Enrollment
Children 2-11 years of age with SCA (HbSS, HbSβ0-thalassmia, HbSOArab, or HbSD) and 
conditional TCD velocities were recruited between May 2012 and August 2013 at three 
sites: St. Jude Children’s Research Hospital (St. Jude), Memphis, TN, US; Sickle Cell Unit, 
Tropical Medicine Research Institute (TMRI), University of the West Indies, Kingston, 
Jamaica; and Instituto de Hematologia Arthur Siqueira Cavalcanti (HEMORIO), Rio de 
Janeiro, RJ, Brazil (recruitment brochure provided as supplemental material). To meet study 
eligibility, a screening TCD exam with conditional TCD velocity was required within 3 
months of enrollment. Participants were excluded for prior history of abnormal TCD 
velocities or clinical stroke, red blood cell transfusion within 2 months of enrollment, 
concurrent use of another anti-sickling medication, or contra-indication to hydroxyurea 
therapy (allergy, pregnancy, renal insufficiency). In addition, patients were temporarily 
excluded from enrollment for profound anemia and/or cytopenias [hemoglobin (Hb) 
concentration <6 g/dL, absolute reticulocyte count (ARC) <100 × 109/L with Hb 
concentration <8.0 gm/dL, white blood cell count (WBC) <3.0 × 109/L, absolute neutrophil 
count (ANC) <1.0 × 109/L, or platelet count <100 × 109/L]. All participants received 
standard age-appropriate care for SCA (penicillin prophylaxis, pneumococcal immunization, 
and disease education) as per local standards of care.
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TCD Exam Procedure and Study Coordination
SCATE was a Phase III, randomized, open label, partially masked, multi-center, 
international, prospective trial of hydroxyurea versus observation for children with SCA and 
centrally confirmed conditional TCD velocities. The study was partially masked in the 
following fashion: (1) all site TCD examiners and central TCD reviewers were masked to 
the assigned treatment arm; and (2) all site clinicians were masked to the participants’ serial 
TCD results.
All three sites used a standardized TCD examination protocol with identical equipment 
(Sonaratek TCD system, software version 6.68, Middleton, WI). The TCD examiners from 
each site received standardized training, and all were required to pass a certification process 
to ensure proficiency in performing the examinations according to the SCATE protocol. The 
TAMV was obtained bilaterally in five arteries: middle cerebral artery (MCA), anterior 
cerebral artery (ACA), posterior cerebral artery (PCA), internal carotid artery (ICA), and 
internal carotid bifurcation (Bif). All exams were scored locally and sent electronically to 
the Data Coordinating Center (DCC) by secure data transfer, and then de-identified and 
uploaded to the TCD Core for review and scoring.
Pre-enrollment screening TCD exams were performed at each clinical site as per normal 
practice. When a conditional TCD velocity was identified, the child and family were 
approached regarding enrollment in the trial. After informed consent, this exam was 
reviewed centrally to confirm the conditional velocity. Additional TCD exams were then 
performed to document a second conditional velocity. Two independent exams with 
conditional velocities were required within 6 months to proceed to randomization. Once 
randomized, follow-up TCD exams were performed every 3 months thereafter 
(supplemental Figure 1). All TCD exams were evaluated by the TCD Core and masked to 
study site, subject demographics, and clinical status.
The SCATE study used a remote internet-based data capture system with secure data entry 
and storage in a central database maintained by the DCC. Hydroxyurea was provided in 
capsules of different sizes (300 mg, 400 mg, and 500mg) to facilitate dosing and were 
purchased from Bristol-Myers Squibb (New York, NY). Hydroxyurea powder was obtained 
from UPM Pharmaceuticals (Baltimore, MD) and used for reconstitution as a liquid 
formulation (100 mg/mL).(14) A Central Pharmacy distributed the study drug (capsules and 
powder) to all sites and monitored drug expiration.
The Medical Coordinating Center (MCC) ensured quality of the data, timely data entry, 
guidance to sites in following the protocol with regards to hydroxyurea dosing, and ongoing 
monitoring of adverse events. The study was approved by the Institutional Review Board of 
all participating institutions, and informed consent was signed by all guardians of the 
children, prior to any study-related activities. An independent Data Safety Monitoring Board 
evaluated the unblinded study results for safety and study endpoints.
Study Endpoints
The primary endpoint of the SCATE trial was the cumulative incidence of conversion to 
abnormal maximum TAMV velocities (in any of the 10 vessels measured). Secondary 
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endpoints included: (1) changes in serial TCD velocities; (2) cumulative incidence of 
neurological and non-neurological acute events including stroke; and (3) health-related 
quality of life (HRQOL). The MCC informed the site clinicians once subjects met the 
primary endpoint of the study (conversion to abnormal maximum TAMV velocities), at 
which point the subject was removed from the study.
Study Procedures and Evaluation
After randomization, participants received hydroxyurea treatment or observation, planned 
for a total of 30 months. Monthly physical exams and laboratory tests (monthly complete 
blood counts and reticulocyte counts and bi-monthly chemistries) were performed locally. 
Hb identification using high performance liquid chromatography with quantitation of HbA, 
HbS, and fetal Hb (HbF) was obtained quarterly and centrally analyzed. For subjects 
randomized to the alternative (hydroxyurea) arm, the initial drug dose was 20 mg/kg/day 
and escalated to maximum tolerated dose (MTD) at 5 mg/kg/day increments to a dose not to 
exceed 35 mg/kg/day.(15) MTD was defined as the daily dose leading to mild neutropenia 
(ANC 2.0 to 4.0 × 109/L), without reaching pre-defined thresholds of hematological toxicity, 
defined as ANC <1.0 × 109/L, Hb concentration <7.5 gm/dL with absolute reticulocyte 
count <100 × 109/L, platelets <80 × 109/L, or ARC <80 × 109/L with hemoglobin 
concentration <8.5 gm/dL. Hydroxyurea dose was held for one week if hematological 
toxicity occurred, and restarted at the same dose or with a 10% reduction if toxicity recurred. 
Hydroxyurea adherence (%) was assessed through calculation of returned doses, divided by 
the dispensed amount, at every study visit.
Statistical Considerations
The SCATE study was designed to have a 5% chance (α = 0.05) of falsely concluding that 
hydroxyurea reduces the cumulative incidence of conversion to abnormal TCD velocity, 
when in fact there is no difference between the hydroxyurea and standard treatment groups; 
and at least 80% (= 1 − ß) power to correctly conclude that hydroxyurea reduces the 
cumulative incidence of conversion to abnormal TCD velocity, given the true effect is at 
least a three-fold reduction in cumulative incidence after 30-months. Assuming a 5% per 
year dropout rate, 100 randomized participants were required to demonstrate that 
hydroxyurea reduces the cumulative incidence of conversion to abnormal TCD velocity. 
Children were randomized at a 1 to 1 ratio and used an adaptive blocked randomization 
algorithm. The intention-to-treat principle was followed and all eligible, randomized 
participants were analyzed as randomized, in the primary analysis. As a secondary post-hoc 
analysis, participants were analyzed according to the actual treatment received (hydroxyurea 
versus observation), since two children were randomized but did not receive treatment with 
hydroxyurea due to unavailability of study drug at one site. The exact log-rank test (1-sided) 
was used to compare the cumulative incidence of conversion to abnormal TCD velocity. The 
exact Wilcoxon-Mann-Whitney test was used to compare the other secondary outcomes of 
longitudinal TCD velocity changes, acute events, and standardized z-scores for weight, 
height, and body mass index (BMI).
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RESULTS
Participant Characteristics and Treatment Allocation
During the period of study enrollment from May 2012 to August 2013, a total of 1234 
children received TCD screening across all three participating sites. There were 1062 (86%) 
children with normal, 115 (9%) with conditional, and 24 (2%) with abnormal TCD 
velocities, while 33 (3%) were technical failures (Figure 1).
Among the 115 children with conditional TCD exams identified during screening, 38 
enrolled (18 from Jamaica, 13 from Brazil, and 7 from the US) and 22 were randomized to 
either hydroxyurea or observation. There were 4 children who dropped out during screening 
(due to not having a confirmatory TCD), while 12 were in screening at the time of study 
closure (Figure 1). The median age at enrollment was 5.4 years (range 2.7 to 9.8 years). 
Most participants were female (25/38) and their self-reported races were 28 black and 10 
white, reflecting the demographics of the international clinical sites. Genotypes included 
HbSS (36), HbSβ0-thalassemia (1), and HbSD (1). The demographics and laboratory 
findings at baseline are shown in Table 1.
Premature Study Termination
There was a regulatory delay of 18 months preventing importation of the study drug 
(hydroxyurea) at one site (HEMORIO). This delay was due to numerous administrative 
difficulties in obtaining formal approval by ANVISA (Agência Nacional de Vigilância 
Sanitária), the Brazilian government agency responsible for authorizing the entry of study 
drugs into the country. The SCATE study opened for enrollment in May 2012, and in 
August 2013 the study was suspended for new enrollments and randomization by the 
sponsor for slow patient accrual. The study was terminated in January 2014 due to slow 
accrual and the unlikelihood of meeting the study’s enrollment target and primary endpoint 
within the timeframe of funding. Due to the administrative delay in obtaining drug approval 
in Brazil, 2 of the 11 children randomly allocated to the treatment arm (hydroxyurea) did not 
initiate study drug as per protocol.
Hematological Effects of Hydroxyurea
The median MTD for the 9 participants who received hydroxyurea was 25 mg/kg/day (range 
20 – 35 mg/kg/day). Calculated % adherence, based on data from 92 of 112 total study visits 
for those who were randomized and received hydroxyurea, was 100% (for both mean and 
median). Exit versus baseline median differences in hematological indices for children 
receiving hydroxyurea showed expected significant increases in Hb concentration, HbF, and 
MCV, along with significant reductions in WBC and ANC in comparison with those who 
did not receive hydroxyurea (Table 2). There were no significant differences in renal or 
hepatic function tests between the treatment arms.
Primary Study Endpoint
The cumulative incidences of conversion from conditional to abnormal TAMV were 9% 
(95% CI 0 to 35%) and 47% (95% CI 6 to 81%) in the hydroxyurea and observation arms 
after 15 months, respectively (p = 0.16, Figure 2A). However, none of the participants 
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assigned to the hydroxyurea arm who actually received the drug converted to abnormal TCD 
velocities, whereas three in the observational arm did (supplemental Table 1). In post-hoc 
analysis according to treatment received, hydroxyurea treatment was associated with a 
significantly lower risk of conversion to abnormal TAMV after 15 months, 0% versus 50% 
(95% CI 9 to 82%), (p = 0.02, Figure 2B).
Secondary Endpoints
All secondary endpoints were evaluated using the intention-to-treat analysis and compared 
from randomization to last observation. After a mean of 10.1 months (median 8.7, range 0.5 
to 17 months), participants randomized to the hydroxyurea arm had a mean reduction of 
TAMV values of 15.5 cm/sec (95% CI -32.0 to 1.1 cm/sec), whereas those in the 
observation arm had a mean increase in velocity of 10.2 cm/sec (95% CI -4.8 to 25.2 cm/
sec) (p = 0.02, Figure 3).
No strokes or transient ischemic attacks occurred. The only three new neurological events 
were dizziness (one event in the hydroxyurea arm) and headaches (one in each arm), with no 
significant difference between the two arms. Vaso-occlusive events (pain and acute chest 
syndrome) were more common in the observation arm than in the hydroxyurea arm (5 
versus 2, respectively), but not significantly different. Two cases of acute splenic 
sequestration occurred, one in each arm.
Due to the early study termination, HRQOL was not sufficiently collected at study exit, 
therefore due to insufficient data points, no analyses could be performed regarding changes 
in HRQOL during the study.
Growth parameters of children from all 3 sites plotted within normal limits throughout the 
study when using the World Health Organization Child Growth Standards (http://
www.who.int/childgrowth). There was no significant difference between the hydroxyurea 
and observation arms in the z-scores for weight, height, and BMI at baseline and last follow-
up (Supplemental Table 2).
Adverse Events and Drug Toxicity
One subject on the hydroxyurea arm had one episode of transient neutropenia (ANC <1.0 × 
109/L), vs. none on the observation arm. There were two cases of reticulocytopenia with 
worsened anemia (one in each arm), and no thrombocytopenia. There were two cases of 
parasite infestation (both hookworm), one in each arm of the study, both treated and with 
complete resolution of symptoms. Among those randomized to hydroxyurea who actually 
received the drug, only one required blood transfusion (due to an episode of worsened 
anemia during influenza B infection marrow suppression), and three subjects not treated 
with hydroxyurea received erythrocyte transfusions (two secondary to acute chest syndrome 
and one due to exacerbated anemia in the setting of a viral illness) (p=NS).
DISCUSSION
To our knowledge, SCATE is the first international NHLBI-sponsored Phase III randomized 
multi-center study in pediatric SCA involving limited-resource countries. Because the study 
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was closed early by the sponsor despite active patient accrual and screening, there were 
insufficient data to demonstrate a significant reduction in the cumulative incidence of 
conversion from conditional to abnormal TCD velocities using intention-to-treat analysis. 
When considering only those who received hydroxyurea (post-hoc analysis), however, there 
was a significant difference in cumulative incidence of conversion from conditional to 
abnormal TCD velocities. In addition, we observed that hydroxyurea treatment significantly 
reduced conditional TCD velocities, an important finding suggested by retrospective and 
single-arm observational studies.(8-13) SCATE extends these prior observations by 
demonstrating prospectively in a randomized phase III trial that hydroxyurea reduces TCD 
velocities and may, thereby, lower the risk of primary stroke. By sparing the commonly 
observed conversion to abnormal TCD elevation, hydroxyurea therapy for conditional TCD 
velocities could obviate the need for chronic and indefinite transfusion therapy in many 
young patients with SCA, which represents an important cost-savings to the medical systems 
of both low- and high-resource countries.
While hydroxyurea is the only commercially available drug for the treatment of SCA, and 
can now be offered to most adults and children 9 months and older,(16) it is far from the 
standard of care. Hydroxyurea is still largely unavailable in many countries and thus 
underutilized, especially in resource-poor areas of the world. To help the impact of 
hydroxyurea treatment be fully realized by the global sickle cell disease community, it is 
important to gather prospective data regarding its safety and efficacy in more geographical 
locations and clinical settings, which will ultimately define its future indications and 
motivate its broader use.
Children with conditional TCD velocities represent a group of patients for whom treatment 
is not formally recommended (as opposed to those with abnormal TCD velocities) and 
therefore remain untreated despite an elevated risk for a primary stroke. The cumulative 
conversion rate in our patient sample was higher than in prior reports (30 and 50% versus 10 
and 23% at 12 and 18 months, respectively).(5) This difference likely reflects the smaller 
sample size of this study, but also the fact that our populations derive from different 
countries, possibly adding genetic variability that contributed to the higher cumulative 
conversion rates.
Hydroxyurea induces fetal hemoglobin production and decreases intracellular HbS polymers 
within sickle erythrocytes.(17) Hydroxyurea has a number of additional beneficial effects 
besides induction of HbF, including decreased neutrophil and reticulocyte counts caused by 
marrow cytotoxicity, interference with red blood cell and leukocyte adhesion to the 
endothelium,(18;19) reduction of inflammatory cytokines,(20) and increased release of the 
vasodilator, nitric oxide.(21) Clinical benefits of hydroxyurea have been shown in both 
children and adults through reduction of frequency of pain and acute chest syndrome 
episodes.(12;22;23) Similar to prior studies in children with SCA, laboratory benefits from 
hydroxyurea in the SCATE trial also included increases in Hb concentration, HbF, MCV, 
and reduction in ANC.(12;24) The beneficial effect of increasing the Hb concentration in the 
hydroxyurea-treated arm may have contributed to the observed TAMV reduction. The use of 
hydroxyurea in SCA is especially attractive for low-resource settings due to its ease of oral 
administration, potential for reducing medical cost, and safety profile.(25) In the SCATE 
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study, toxicities from hydroxyurea were uncommon and no different than reported in other 
pediatric populations (<10% severe neutropenia and reticulocytopenia).(26-29) Other 
adverse events during the study (neurological and non-neurological) were also rare and not 
observed in any greater frequency than prior studies.(24;26)
The SCATE study explored a new paradigm for collaborative multi-center clinical research 
in SCA. Although prematurely interrupted, SCATE highlighted the challenges and 
opportunities for international collaboration. High quality and important scientific questions 
can and should be answered without limitation of geographical borders or economic status 
of a nation. International collaboration facilitates SCA clinical trials for which large sample 
sizes are required, and not easily attained with the relatively smaller number of patients in 
North America and Europe. Inclusion of countries in Africa, South and Central America 
may significantly increase the pool of study participants, although the complexity of such 
trials may also increase.(30) Furthermore, in developing nations, where the burden of SCA 
is far greater than in the developed world, collaborative research participation provides 
overall benefits from improved standards of care, which are likely to impact care beyond the 
objectives of the study.
International collaborative research involving developing countries is an important goal of 
the NHLBI and the American Society of Hematology, particularly for research in SCA.
(31;32) Collaborative research between resource-rich and resource-limited countries brings 
many opportunities to further research expertise and to improve clinical care in 
underprivileged areas of the world.(33) This study had many unique design features and 
challenges, among which was the enrollment of children from three different regions of the 
world with different laws and regulatory governance. This was an ambitious study that 
included centers with large numbers of children with SCA from both developed and 
developing countries. SCATE followed the same rigorous standards of research in all 
participating countries and scientifically investigated a potential new indication for 
hydroxyurea therapy.
Our study, although important in addressing the feasibility of conducting rigorously 
designed international clinical trials, had a limited final sample size for analysis, which 
hindered our ability to reach the primary study endpoint. Of the 115 targeted enrollment for 
SCATE, only 38 had enrolled (33%) at the time of study closure. Barriers to study 
enrollment are multi-factorial, including investigator-patient mistrust, trial design, and 
imbalance of perceived risks and benefits.(34-36) In SCATE, there were added complexities 
related to study design, language differences, and prolonged government and regulatory 
approvals of the protocol and drug importation, which hindered the ability to provide study 
treatment. Wider use of hydroxyurea also played a role at the North American site, reducing 
the pool of eligible patients. Because reduction in the TAMV was observed in subjects from 
only 2 sites, generalizability of our findings is limited. Despite its limitations, an important 
strength of SCATE includes the establishment of an infrastructure that allowed high-quality 
research for this trial but also future trials, using the highest scientific standards. Global 
efforts, such as that of the Global Sickle Cell Disease network (http://
www.globalsicklecelldisease.org) should build on the experience of the SCATE trial to 
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create future successful international studies that will answer relevant questions for 
individuals living with SCA worldwide.
In summary, we demonstrated in a phase III randomized clinical trial that hydroxyurea 
reduces TAMV in children with SCA and conditional TCD velocities. Hydroxyurea should 
be considered for treatment of children with conditional TCD velocities. Future international 
multicenter studies should build on the lessons learned through SCATE to develop 
additional and relevant clinical trials for people living with SCA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Consort diagram of the SCATE study
* These 12 subjects were either not yet confirmed or already centrally confirmed as 
conditional TCD, but not randomized due to early study suspension and later study closure. 
**Two subjects did not receive hydroxyurea due to drug unavailability at one of the sites.
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Figure 2. Cumulative incidence of conversion to abnormal TCD
B> A. In the intention-to-treat analysis, conversion to abnormal TCD velocity was higher in 
the observation arm, but not statistically significant (p=0.17). B. In the post-hoc as-treated 
analysis, conversion to abnormal TCD velocity was significantly higher in the observation 
arm (p=0.02).
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Figure 3. Change in TCD velocity according to treatment
B> Children randomized to hydroxyurea had a mean reduction of 15.5 cm/sec, whereas 
those on the observation arm had a mean increase of 10.2 cm/sec (p=0.02).
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Table 1
Patient Characteristics at Baseline.
Variable Randomization arm
Hydroxyurea (N=11) Observation (N=11)
Age (years)
6.2 (2.4) 6.6 (1.5)
Gender (n,%)
Males 4 (36) 4 (36)
Females 7 (64) 7 (64)
Ethnicity (n,%)
Latino 2 (18) 3 (27)
Non-Hispanic 9 (82) 8 (73)
Race (n,%)
Black 10 (91) 9 (82)
White 1 (9) 2 (18)
Genotype (n,%)
HbSS 11 (100) 10 (91)
HbSβ0thalassemia 0 (0) 1 (9)
Hematologic indices
Hb (g/dL) 7.5 (0.9) 7.7 (1.0)
MCV (fL) 85.9 (5.0) 84.9 (10.8)
ARC (×109/L) 316.8 (73.22) 381.3 (139.73)
WBC (×109/L) 14.2 (4.0) 13.1 (4.9)
ANC (×109/L) 5.9 (2.0) 4.9 (1.9)
Platelets (×109/L) 474.2 (126.2) 388.1 (151.8)
HbF (%) 9.9 (6.7) 9.4 (6.1)
TCD Values
Overall TAMV (cm/sec) 183.5 (8.5) 181.8 (6.4)
Right side TAMV (cm/sec) 167.0 (15.1) 172.7 (14.9)
Left side TAMV (cm/sec) 175.3 (3.9) 174.5 (15.6)
Notes: ANC: absolute neutrophil count, Hb: hemoglobin, MCV: mean corpuscular volume, ARC: absolute reticulocyte count, WBC: white blood 
cell count, TAMV: time-averaged mean velocity. Results presented as mean (SD), unless otherwise specified. There were no significant differences 
between both arms.
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